5611-51-8

Eye ContactCheck for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at
least 15 minutes. Get medical attention if irritation occurs.
Skin ContactWash with soap and water. Cover the irritated skin with an emollient. Get medical attention if irritation develops.
Serious Skin ContactNot available.
InhalationIf inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get
medical attention.
Serious InhalationNot available.
IngestionDo NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an
unconscious person. If large quantities of this material are swallowed, call a physician immediately. Loosen tight
clothing such as a collar, tie, belt or waistband.
Serious IngestionNot available.

---

Section 5. Fire and Explosion Data
Flammability of the Product May be combustible at high temperature.
Auto-Ignition Temperature Not available.
Flash PointsNot available.
Flammable LimitsNot available.
Products of CombustionThese products are carbon oxides (CO, CO2), halogenated compounds.
Fire Hazards in Presence of Slightly flammable to flammable in presence of heat.
Various SubstancesNon-flammable in presence of shocks.
Explosion Hazards in Presence Slightly explosive in presence of open flames and sparks.
Non-explosive in presence of shocks.
of Various Substances
SMALL FIRE: Use DRY chemical powder.
Fire Fighting Media
and InstructionsLARGE FIRE: Use water spray, fog or foam. Do not use water jet.
As with most organic solids, fire is possible at elevated temperatures
Special Remarks on
Fire Hazards
Special Remarks on Explosion Fine dust dispersed in air in sufficient concentrations, and in the presences of an ignition source is a potential dust
Hazardsexplosion hazard.

---

Section 6. Accidental Release Measures
Small SpillUse appropriate tools to put the spilled solid in a convenient waste disposal container. Finish cleaning by
spreading water on the contaminated surface and dispose of according to local and regional authority
requirements.
Large SpillUse a shovel to put the material into a convenient waste disposal container. Finish cleaning by spreading water
on the contaminated surface and allow to evacuate through the sanitary system.
Triamcinolone Hexacetonide

---

Section 7. Handling and Storage
PrecautionsKeep away from heat. Keep away from sources of ignition. Do not breathe dust.
StorageKeep container tightly closed. Keep container in a cool, well-ventilated area.

---

Section 8. Exposure Controls/Personal Protection
Engineering ControlsUse process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below
recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to
airborne contaminants below the exposure limit.
Personal ProtectionSafety glasses. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. Gloves.
Personal Protection in Case of Splash goggles. Full suit. Dust respirator. Boots. Gloves. A self contained breathing apparatus should be used
a Large Spillto avoid inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist
BEFORE handling this product.
Exposure LimitsNot available.

---

Section 9. Physical and Chemical Properties
Physical state and appearance Solid. (Crystalline powder.)OdorOdorless.
TasteNot available.
Molecular Weight532.64 g/mole
White. Off-white.
Color
Not available.
pH (1% soln/water)
Boiling PointNot available.
Decomposition temperature: 295°C (563°F)
Melting Point
Critical TemperatureNot available.
Specific GravityNot available.
Vapor PressureNot applicable.
Vapor DensityNot available.
VolatilityNot available.
Odor ThresholdNot available.
Not available.
Water/Oil Dist. Coeff.
Ionicity (in Water)Not available.
Dispersion PropertiesNot available.
SolubilityInsoluble in cold water, hot water.

---

Section 10. Stability and Reactivity Data
StabilityThe product is stable.
Not available.
Instability Temperature
Conditions of InstabilityNot available.
Incompatibility with variousNot available.
substances
CorrosivityNot available.
Triamcinolone Hexacetonide
Not available.
Special Remarks on
Reactivity
Not available.
Special Remarks on
Corrosivity
PolymerizationWill not occur.

---

Section 11. Toxicological Information
Routes of EntryInhalation. Ingestion.
Toxicity to AnimalsLD50: Not available.
LC50: Not available.
Chronic Effects on Humans Not available.
Other Toxic Effects on
Slightly hazardous in case of skin contact (irritant), of ingestion, of inhalation.
Humans
Special Remarks onNot available.
Toxicity to Animals
Special Remarks onMay cause adverse reproductive effects and birth defects (teratogenic) Human: passes through the placenta.
Chronic Effects on Humans
Special Remarks on otherPotential Health Effects:
Toxic Effects on HumansSkin: May cause skin irritation.
Eyes: May cause eye irritation.
Inhalation: May cause respiratory tract irritaition.
Ingestion: May cause gastrointestinal tract irritation with abdominal distension, nausea, vomiting. May cause
ulcerative esophagitis and peptic ulcers. May cause fluid and electrolyte disturbances resulting in sodium
retention, fluid retention, congestive heart failure in susceptible individuals, potassium loss, hypokalemic alkalosis,
increased calcium excretion, mild diuresis, polyuria, polydypsia, hypertension. May cause depression of
appetite/anorexia in contrast to voracious appetite ordinarily encountered with other glucocorticoids. Common
corticosteroids may cause euphoria whereas Triamcinolone may cause mood depression.
May cause steroid myopathy/muscular atrophy with loss of muscle mass and muscle weakness involving
muscles of the thighs, pelvis, and low back, muscle cramps. May cause other musculoskeletal effects such as
Osteoporosis, vertebral conpression fractures, pathologic fractures of long bones. May affect immune
system/immune response and increase the susceptibly to infections. May very rarely cause hypertension,
hyperglycemia, and may affect behavior/central nervous system (excitation, vertigo, headache, convulsions,
psychosis, hallucinations), and eye problems (glaucoma, mydriasis). Dermatologic effects may include impaired
wound healing, thin fragile skin, facial erythema, petechiae and ecchymoses.

---

Section 12. Ecological Information
Not available.
Ecotoxicity
BOD5 and CODNot available.
Products of BiodegradationPossibly hazardous short term degradation products are not likely. However, long term degradation products may
arise.
The products of degradation are more toxic than the product itself.
Toxicity of the Products
of Biodegradation
Special Remarks on theNot available.
Products of Biodegradation
Triamcinolone Hexacetonide

---

Section 13. Disposal Considerations
Waste DisposalWaste must be disposed of in accordance with federal, state and local environmental
control regulations.

---

Section 14. Transport Information
DOT ClassificationNot a DOT controlled material (United States).
Not applicable.
Identification
Not applicable.
Special Provisions for
Transport
DOT (Pictograms)

---

Section 15. Other Regulatory Information and Pictograms
No products were found.
Federal and State
Regulations
CaliforniaCalifornia prop. 65: This product contains the following ingredients for which the State of California has found
to cause cancer which would require a warning under the statute: No products were found.
Proposition 65
Warnings
California prop. 65: This product contains the following ingredients for which the State of California has found
to cause birth defects which would require a warning under the statute: No products were found.
Other RegulationsEINECS: This product is on the European Inventory of Existing Commercial Chemical Substances.
Other ClassificationsWHMIS (Canada) Not controlled under WHMIS (Canada).
DSCL (EEC)This product is not classified according Not applicable.
to the EU regulations.
Health Hazard
HMIS (U.S.A.)1 National Fire Protection
1 Flammability
1 Association (U.S.A.)
Fire Hazard
1 0 Reactivity
Health
Reactivity
0
Specific hazard
Personal Protection
E
WHMIS (Canada)
(Pictograms)
DSCL (Europe)
(Pictograms)
TDG (Canada)
(Pictograms)
Triamcinolone Hexacetonide
ADR (Europe)
(Pictograms)
Protective Equipment
Gloves.
Lab coat.
Dust respirator. Be sure to use an
approved/certified respirator or
equivalent.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

DATA ITEMS CITED :

7

MOLECULAR FORMULA :

C30-H41-F-O7

MOLECULAR WEIGHT :

532.71

WISWESSER LINE NOTATION :

T F5 E5 B666 GO IO RV AHTTTT&J A1 BF CQ E1 FV1OV1X1&1&1 H1 H1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Intramuscular

DOSE :

40 mg/kg

SEX/DURATION :

female 10-13 day(s) after conception

TOXIC EFFECTS :

Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)

REFERENCE :

JOANAY Journal of Anatomy. (Cambridge Univ. Press, 32 E. 57th St., New York, NY 10022) V.51- 1916- Volume(issue)/page/year: 128,747,1979

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Intramuscular

DOSE :

40 mg/kg

SEX/DURATION :

female 10-13 day(s) after conception

TOXIC EFFECTS :

Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

REFERENCE :

JOANAY Journal of Anatomy. (Cambridge Univ. Press, 32 E. 57th St., New York, NY 10022) V.51- 1916- Volume(issue)/page/year: 128,747,1979

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Intramuscular

DOSE :

2 mg/kg

SEX/DURATION :

female 8 day(s) after conception

TOXIC EFFECTS :

Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

REFERENCE :

46IEAC "Current Research Trends in Prenatal Craniofacial Development, Proceedings of an International Conference, 1980," Pratt, R.M., and R.L. Christiansen, eds., New York, Elsevier Science Pub. Co., Inc., 1980 Volume(issue)/page/year: -,387,1980

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Intramuscular

DOSE :

2 mg/kg

SEX/DURATION :

female 8 day(s) after conception

TOXIC EFFECTS :

Reproductive - Specific Developmental Abnormalities - skin and skin appendages Reproductive - Specific Developmental Abnormalities - musculoskeletal system

REFERENCE :

JDREAF Journal of Dental Research. (International Assoc. for Dental Research, 734 15th St., NW, Suite 809, Washington, DC 20005) V.1- 1919- Volume(issue)/page/year: 58(Spec Iss A),384,197

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Intramuscular

DOSE :

2 mg/kg

SEX/DURATION :

female 12 day(s) after conception

TOXIC EFFECTS :

Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

REFERENCE :

IMNGBK Immunogenetics. (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.1- 1974- Volume(issue)/page/year: 13,443,1981 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5557 No. of Facilities: 17 (estimated) No. of Industries: 1 No. of Occupations: 3 No. of Employees: 1088 (estimated) No. of Female Employees: 744 (estimated)